why choose us

First received: January 09, 2026

Clinical Trial: Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Transfusion Dependent Beta Thalassemia

Study Type: INTERVENTIONAL


Official Title: Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

Brief Summary: Blood transfusion and iron-chelation therapy have prolonged and improved the quality of life in patients with ?-thalassemia.The improvement was mainly due to the decrease in mortality from heart failure Such a treatment, however, leads to chronic iron overload and frequently to endocrine complications, especially the development of diabetes.The prevalence of diabetes mellitus (DM) in ?-thalassemia varies from 9.7% to 29% and the overall prevalence of impaired fasting glucose (IFG) and impaired glucose tolerance…

Read more